Hypertrophic cardiomyopathy (HCM) is characterized by the presence of increased thickness of the left ventricular wall that is not solely explained by abnormal loading conditions. Two-thirds of the patients with HCM have an obstruction in the left ventricle after provocation or even while at rest. This obstruction is associated with more symptoms and a worse prognosis. The two main therapeutic approaches for treating a left ventricular obstruction are alcohol septal ablation and surgical myectomy. Both these techniques are discussed in this article. Currently, the final decision concerning the optimal invasive therapy for patients with obstructive HCM must be individualized to each patient depending on his/her wishes and expectations, way of life, age, heart morphology, and hemodynamics, as well as the experience of the treating center.

Department of Cardiology Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Gersh B J, Maron B J, Bonow R O. et al.American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783–e831. PubMed

Elliott P M, Anastasakis A, Borger M A. et al.Authors/Task Force members; Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J. 2014;35(39):2733–2779. PubMed

Fifer M A, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32(9):1059–1064. PubMed

Anastasakis A, Theopistou A, Rigopoulos A. et al.Sudden cardiac death: investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort. Hellenic J Cardiol. 2013;54(4):281–288. PubMed

Maron B J, Rowin E J, Casey S A. et al.Risk stratification and outcome of patients with hypertrophic cardiomyopathy >= 60 years of age. Circulation. 2013;127(5):585–593. PubMed

Zemánek D, Tomasov P, Homolová S, Linhartová K, Veselka J. Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(9):684–687. PubMed

Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature. Med Sci Monit. 2007;13(4):RA62–RA68. PubMed

Veselka J, Lawrenz T, Stellbrink C. et al.Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2013;29(11):1415–1421. PubMed

Veselka J, Lawrenz T, Stellbrink C. et al.Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study. Catheter Cardiovasc Interv. 2014;84(1):101–107. PubMed

Ball W, Ivanov J, Rakowski H. et al.Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58(22):2313–2321. PubMed

Watkins H, McKenna W J. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):477–479. PubMed

Kirklin J W, Ellis F H Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation. 1961;24:739–742. PubMed

Morrow A G, Brockenbrough E C. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181–189. PubMed PMC

Ommen S R, Maron B J, Olivotto I. et al.Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–476. PubMed

Kwon D H, Smedira N G, Thamilarasan M, Lytle B W, Lever H, Desai M Y. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg. 2010;140(2):317–324. PubMed

Desai M Y, Bhonsale A, Smedira N G. et al.Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–216. PubMed

Maron B J, Maron M S. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–255. PubMed

Panaich S S, Badheka A O, Chothani A. et al.Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample 1998–2010) Am J Cardiol. 2014;114(9):1390–1395. PubMed

Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–214. PubMed

Kuhn H J. The history of alcohol septal ablation. Cardiovasc Revasc Med. 2010;11(4):260–261. PubMed

Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesař D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol. 2005;95(5):675–678. PubMed

Veselka J, Zemánek D, Tomašov P, Homolová S, Adlová R, Tesař D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv. 2010;75(4):546–550. PubMed

Veselka J, Tomašov P, Zemánek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol. 2011;27(6):763–767. PubMed

Kuhn H, Lawrenz T, Lieder F. et al.Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10.  year experience. Clin Res Cardiol. 2008;97(4):234–243. PubMed

Faber L, Welge D, Fassbender D, Schmidt H K, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96(12):864–873. PubMed

Veselka J, Zemánek D, Tomašov P, Duchonová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009;24(1):27–31. PubMed

Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35(30):2040–2045. PubMed

Jensen M K, Havndrup O, Hassager C. et al.Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy. Scand Cardiovasc J. 2011;45(3):153–160. PubMed

Sorajja P, Ommen S R, Holmes D R Jr. et al.Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374–2380. PubMed

Jensen M K, Prinz C, Horstkotte D. et al.Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99(14):1012–1017. PubMed

Three-Dimensional Heart Printing for Planning of Septal Reduction Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy